Skip to content

Walking Program in Fatty Liver Children With Phenylketonuria

Walking Program in Fatty Liver Children With Phenylketonuria: Response of Liver Enzymes

Status
Recruiting
Phases
NA
Study type
Interventional
Source
ClinicalTrials.gov
Registry ID
NCT06718842
Enrollment
40
Registered
2024-12-05
Start date
2024-09-15
Completion date
2025-01-30
Last updated
2024-12-05

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Non Alcoholic Fatty Liver, Phenylketonurias

Brief summary

phenylketonuria (commonly known as PKU) is an inherited disorder that increases the levels of a substance called phenylalanine in the blood. PKU is usually associated with many metabolic complication including non-alcoholic fatty liver

Detailed description

this study will include PKU children sufferers 9n=40) with non-alcoholic fatty liver to be randomly assigned to group I (n=20) that will perform walking program (online supervised free walking that will be applied daily for eight weeks) or group II (N=20) that will act as waitlisted children

Interventions

BEHAVIORALwalking free online supervised program

this Group I will include PKU children sufferers (n=20) with non-alcoholic fatty liver that will perform walking program (online supervised free walking that will be applied daily for eight weeks)

Sponsors

Cairo University
Lead SponsorOTHER

Study design

Allocation
RANDOMIZED
Intervention model
PARALLEL
Primary purpose
TREATMENT
Masking
SINGLE (Outcomes Assessor)

Eligibility

Sex/Gender
ALL
Age
9 Years to 12 Years
Healthy volunteers
No

Inclusion criteria

* PKU children * obese children * fatty liver children (non-alcoholic fatty liver)

Exclusion criteria

* cardiac children * diabetic children * neurogenic disorders * respiratory and renal problems

Design outcomes

Primary

MeasureTime frameDescription
alanine transamianseit will be assessed after eight weeksit is a serum liver enzyme

Secondary

MeasureTime frameDescription
aspartate tranaminaseit will be assessed after eight weeksit is a serum liver enzyme
Gamma-glutamyl Transferaseit will be assessed after eight weeksit is a serum liver enzyme
alkaline phosphataseit will be assessed after eight weeksit is a serum liver enzyme
triglyceridesit will be assessed after eight weeksit will be measured in the serum
body mass indexit will be assessed after eight weeksit will be measured after emptying bladder

Countries

Egypt

Contacts

Primary ContactAli Isamil, Lecturer
ali.mohamed@pt.cu.edu.eg0201005154209
Backup Contactshimaaa bondok, PHD
dr.shymaa_bondok@yahoo.com02 101 565 5118

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026